Verified by AISci
Public source attached
Source status for this paper in the current AISci reviewed snapshot.
- Primary source
- ClinicalTrials.gov
- Correction status
- none
- Evidence coverage
- 1 sources / 1 publishers
- Last metadata check
- Jul 19, 2026
clinical trialBiotech
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (NCT07468136)
Source-permitted summary
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | Phase: PHASE1 | Conditions: Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4
SourceClinicalTrials.govAI Reading Notes
Core signal
Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.
- Core signal
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | Phase: PHASE1 | Conditions: Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4
- Field context
- Protein and Drug Design
- People and labs
- Not stated in the reviewed source.
- Why it matters
- Clinical trial registry updates are translation signals, not commercialization claims by themselves.
- Limits to check
- ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.
Research Workflow
Research Workflow
Recommended next steps for turning this signal into research action.
- Read original source
- Check DOI/OpenAlex
- Open relationship graph
- Review people and labs: Not stated in the reviewed source.
- Open linked event for AISci context
- Prepare journal-club PPT: AISci action coming next
- Plan replication checks: AISci action coming next
Publication facts
- Type
- clinical trialSourceClinicalTrials.gov
- Date
- Jun 24, 2026SourceClinicalTrials.gov
- Venue
- ClinicalTrials.govSourceClinicalTrials.gov
- Open access
- openSourceClinicalTrials.gov
External IDs
Author order
No reviewed author edge is attached to this output.
Organizations
No source-confirmed author affiliation is attached.
Related events
Topics
Relationship evidence
Protein and Drug Design
Controlled AISci Stage A topic for Protein and Drug Design.
Mayo Clinic
Organization linked by public source evidence.
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Clinical/translation signal: Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Timeline
- clinical trialRetifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas